Comorbid diseases can affect breast cancer prognosis. We conducted a population-based study of Danish women diagnosed with a first primary breast cancer from 1995 to 2005 (n ¼ 9300), using hospital discharge registry data to quantify comorbidities by Charlson score. We examined the influence of comorbidities on survival, and quantified their impact on relative mortality rates. The prevalence of patients with a Charlson score ¼ '0' fell from 86 to 81%, with an increase in those with Charlson score ¼ '1 -2' from 13 to 16%, and score ¼ '3 þ ' from 1 to 2%. One-and five-year survival for patients with Charlson score ¼ '0' and '1 -2' was better for those diagnosed in 1998 -2000 than in 1995 -1997 . Similar findings were observed for 5-year age-adjusted mortality. Additional analyses, adjusted for stage, indicated that confounding by stage could not explain these findings. Despite continued improvements in breast cancer survival, we found a trend of poorer survival among breast cancer patients with severe comorbidities even after adjusting for age and stage. Such poorer survival is an important public health concern and can be expected to worsen as the population ages.
Breast cancer accounts for a substantial proportion of the cancer burden, with over 1 000 000 new cases diagnosed and over 400 000 breast cancer-related deaths worldwide each year (Parkin et al, 2005) . Denmark has the highest age-standardised breast cancer incidence rate, and one of the highest mortality rates in the world (Globocan, 2006; National Board of Health, 2006) . Over 50% of newly diagnosed breast cancers occur in women aged 60 years or older. Many of these women have coexistent diseases (comorbidities) at the time of their breast cancer diagnosis, which can substantially influence their diagnostic work-up, treatment options, and survival (West et al, 1996; Potosky et al, 2002; Harlan et al, 2003a; Louwman et al, 2005) . The presence of comorbidities at diagnosis can have a negative impact on prognosis and survival (West et al, 1996; Cronin et al, 2005) , and two small studies have indicated that breast cancer patients with comorbid conditions have lower survival compared to those without comorbidities (Charlson et al, 1987; West et al, 1996) .
The change in population demographics, in terms of population aging (Coebergh, 1996) , will result in an increased proportion of elderly cancer patients, many of whom present with comorbid diseases. A study by Louwman et al (2005) indicated that 10% of patients aged less than 50 years had comorbid conditions compared to 55% of patients aged over 80 years.
We present a population-based study of the impact of comorbidity (as measured by the Charlson comorbidity score, originally validated using 10-year survival in breast cancer patients) on breast cancer survival and mortality in a Danish population from 1995 to 2005 (Charlson et al, 1987) . We examine trends in breast cancer survival and mortality over three time periods.
MATERIALS AND METHODS

Study population
We identified all patients with a diagnosis of breast cancer (ICD-8 code 174.xx and ICD-10 code C50.x) from 1 January 1995 through 31 March 2004, using the hospital discharge registries of four Danish counties; North Jutland, Aarhus, Viborg, and Ringkjøbing. In Denmark, all health-related services are registered to individual patients by use of their civil personal registry number (CPR), assigned to all Danish citizens since 1968, which denotes gender and date of birth. This unique CPR number facilitates linkage between population-based registries (Gaist et al, 1997) . The registries include all non-psychiatric hospital admissions (since 1977) and outpatient hospital visits (since 1995). Information is recorded immediately after discharge and includes CPR number, dates of admission and discharge, and up to 20 discharge diagnoses (Andersen et al, 1999) . Diagnoses are classified according to the International Classification of Diseases (ICD), 8th revision until the end of 1993 and the 10th revision thereafter.
Comorbidities at diagnosis
We included information on comorbidities up to 10 years before breast cancer diagnosis. Comorbidities were identified using the hospital discharge registries of each county and were categorised using the Charlson index. The index comprises 19 conditions, each weighted according to its potential to influence mortality (Charlson et al, 1987) . We used Deyo's adaptation of the Charlson comorbidity score, which adapts the Charlson clinical comorbidity index for research relying on ICD-10 codes (Deyo et al, 1992) . Breast cancer diagnoses were not included when computing the index. We grouped patients according to a Charlson score of '0', '1 -2', or '3 þ ', groupings which translate into 'mild', 'moderate', and 'severe' illness (Charlson et al, 1987) .
Stage at diagnosis
Information on stage is not included in the hospital discharge registries. To obtain information on breast cancer stage at diagnosis, we used the CPR number to link to the Danish Cancer Registry. The Danish Cancer Registry is a population-based nationwide registry with data on incident cases of cancer in Denmark since 1943, including civil registration number, method of verification of the cancer, stage, and residence at date of cancer diagnosis. The registry receives notifications from hospital departments, institutes of forensic medicine, general practitioners, and practising specialists The registry is not, however, entirely up to date. Data are complete through 2002.
Vital status
We linked members of the study cohort via their CPR number to the Danish Civil Registry to obtain vital status. The Danish Civil Registry is updated daily and has maintained records on vital status, date of death, and the residence of all Danish citizens since 1 April 1968. Follow-up was through patient date of death or 31 January 2005, whichever occurred first.
Statistical analyses
We present distribution frequencies (numbers and percentages) of breast cancer patients in each Charlson score category for each period of diagnosis. We plotted Kaplan -Meier curves for breast cancer patients according to the periods of diagnosis -1995 -1997, 1998 -2000 and 2001 -2004 , age, and comorbidity categories. All time periods were 36 months long, except for the last time period, which included 39 months. We calculated survival at 1 and 5 years by product limit methods for each group, except for 5-year survival for patients diagnosed from 2001 to 2004. We used Cox proportional hazards regression analysis to compute 1-and 5-year crude and age-adjusted hazard ratios as a measure of relative mortality to assess the association of comorbidity with relative mortality using the Charlson score '0' as the reference category in each time period. For the patients with available stage information, we carried out a subanalysis adjusting mortality ratios for both age and stage. Table 1 illustrates the number and percentage of patients for each Charlson comorbidity score by diagnostic period. A total of 9300 breast cancer cases were included, 2819 diagnosed in 1995 -1997, 3003 diagnosed in 1998 -2000, and 3478 diagnosed from 2001 -2004 . The prevalence of patients with Charlson score '0' fell from 86 to 81% over the time period, with corresponding increases in the prevalence of patients with Charlson scores '1 -2' (3% increase) and '3 þ ' (1% increase). For all three time periods, median age at diagnosis did not change for patients with a Charlson score '0' (59 out of 60 years) or a Charlson score '1 -2' (72 out of 73 years). Among patients with a Charlson score '3 þ ', however, there was a gradual increase in the median age at diagnosis with each diagnostic period from age 72 to 76 years in the respective calendar year categories. The highest number of patients resided in Aarhus and North-Jutland Counties because of population demographics. There was a sharp increase in the proportion of patients with a Charlson score '1 -2' in Ringkojbing County from 1995 -1997 to 1998 -2000 from 8 to 14%, and then to 17% in 2001 -2004 . There was an increase in the proportion of breast cancers in the latest period in all counties. Percentages have been rounded to the nearest decimal place and therefore may not sum to 100%.
RESULTS
Comorbidity and breast cancer survival DP Cronin-Fenton et al Table 2 outlines the cumulative proportion of patients surviving at 1-year and 5-years as well as the crude and adjusted relative mortality rates comparing patients with positive Charlson comorbidity scores to those with Charlson score '0'. One-year survival of patients with Charlson score '0' was similar for all three diagnostic periods. Five-year survival was slightly better in patients diagnosed in 1998 -2000 (70%, 95% CI ¼ 68 -72%) compared to those diagnosed in 1995 -1997 (68%, 95% CI ¼ 66 -69%). One-year survival was also better among patients with Charlson score '1 -2' diagnosed in 2001 -2004 compared to those diagnosed during the earlier periods (85 compared to 81% (1998 -2000) and 79% (1995 -1997) ). Among patients with Charlson score '3 þ ', 1-year survival was lowest in those diagnosed from 2001 -2004 (67%, 95% CI ¼ 55 -76%), compared to those diagnosed in 1998 -2000 (80%, 95% CI ¼ 66 -88%) and in 1995 -1997 (72%, 95% CI ¼ 55 -84%).
Patients with non-zero comorbidity scores had poorer survival than those with Charlson score '0' in each diagnostic period. Oneyear relative mortality among patients with Charlson score '1 -2' was higher than that of their Charlson score '0' counterparts; mortality ratio (MR) 1995 -1997 
DISCUSSION
There are two key findings of this population-based study. First, we note a trend of poorer survival from 1995 through 2005 among breast cancer patients with comorbid diseases. To our knowledge, this has not been reported previously. The second key finding is that the overall prognosis for breast cancer patients improved over time after adjusting for age and comorbidity, similar to trends in other populations, where breast cancer survival has improved over time (Sant et al, 2001; Althuis et al, 2005; Olsen et al, 2005) .
Breast cancer survival can be improved via earlier and more adequate diagnosis, and up-to-date guideline concordant treatment. Over the period studied, adjuvant breast cancer treatment adhered to the guidelines of the Danish Breast Cancer Cooperative Group (www.dbcg.dk). There was no population-based mammography screening in the study area. Moreover, there were no major changes to diagnostic techniques in the study population, although the sentinel lymph node biopsy (SLNB) was increasingly used to spare women, with no sign of axillary disease, a full dissection. Such increased use of SLNB may contribute to the increase in regional stage over time for each Charlson category, and may have caused some level of disease upstaging consistent with trends in other countries (Schouten et al, 2002) (CroninFenton et al, 2007 , manuscript in submission). The rising incidence rates of breast carcinoma with micro-metastatic lymph node involvement. Comorbidity and breast cancer survival DP Cronin-Fenton et al
Breast cancer survival has been extensively studied (Bergman et al, 1991a, b; Ewertz, 1993; Carmichael et al, 2004; Althuis et al, 2005; Grant, 2005; Parkin et al, 2005) ; however, a relative paucity of research has investigated the effect of comorbidity on breast cancer and cancer survival generally (Bergman et al, 1991a; West et al, 1996; Yancik et al, 2001) . Our study extends the research from several studies in western populations that indicate a negative impact of comorbidity on cancer survival (Charlson et al, 1987; West et al, 1996; Cronin et al, 2005) . Our findings compare to those of Charlson et al (1987) and West et al (1996) , highlighting the increased risk of mortality associated with mild (Charlson score '1 -2') and severe comorbidity (Charlson score '3 þ ') compared to little/no comorbidity (Charlson score '0'). However, like the West study, we assessed all-cause mortality rather than mortality from causes other than breast cancer as per the Charlson paper. Thus cancer, or its treatment, may accelerate the course of other pathological conditions, resulting in poorer survival.
Studies have indicated that patients with comorbidities are often (West et al, 1996; Potosky et al, 2002; Harlan et al, 2003a; Louwman et al, 2005) , but not always (Lash et al, 2003) , less likely to receive appropriate treatment. Lower survival of patients with comorbidities may be attributable to physician or patient preferences to forego the potential toxicities of cancer-directed therapy, which could further compromise their health and quality of life. Although less treatment of these patients may have a negative impact on their survival -thus our observed poorer survival among patients with comorbidities compared to those with a Charlson score of zero -it is unlikely to influence their survival over time as there has been little change to breast cancer therapy from 1995 to 2004 (www.dbcg.dk).
An interesting finding of our study is the increase in median age of patients with severe comorbidities. However, the prevalence of Table 2 One-year and five-year survival after breast cancer for three comorbidity groups together with 1-and 5-year relative mortality for patients with Charlson scores of 1 -2 and 3+ compared to patients with a Charlson score of 0 for each diagnostic period Table 3 One-year and five-year survival for breast cancer patients in Denmark for three diagnostic periods Comorbidity and breast cancer survival DP Cronin-Fenton et al patients with a Charlson comorbidity score increased only slightly over the period of diagnosis, largely driven by an increased prevalence of patients with Charlson score '1 -2' rather than those with score '3 þ '. The trend of higher mortality among patients with comorbidities remained even after adjusting for age and stage. Breast cancer therapy (and cancer therapy in general) differs according to patient age and menopausal status; older women can be less likely than younger women to receive definitive care for newly diagnosed breast cancer (Bergman et al, 1991a; Havlik et al, 1994; Hurria et al, 2003; Harlan et al, 2003b; Janssen-Heijnen et al, 2005; Louwman et al, 2005) . In Denmark, chemotherapy is not recommended as a standard treatment for hormone receptornegative patients over the age of 70 years. Furthermore, adjuvant therapy is rarely given to patients over the age of 75 years at diagnosis. We note a higher prevalence of patients with unstaged disease had Charlson scores of '1 -2' or '3 þ '. This may suggest that the presence of comorbidity at diagnosis either prevented a full diagnostic work-up or the assignment of an appropriate stage. Moreover, as anticancer therapy is directed by stage at diagnosis, patients with unstaged disease may have received suboptimal cancer treatment. These factors are likely to have exacerbated the prognosis of these patients.
Our findings indicate an increase in the proportion of patients with a comorbidity score between the first and last time periods. This may be attributable to more complete recording of comorbid disease in the hospital discharge registries, or indeed, a higher likelihood that a patient with comorbidities could also be examined for breast cancer.
Confounding by lifestyle factors (obesity, smoking, alcohol consumption) both increase breast cancer risk (Thun et al, 1997; Sonnenschein et al, 1999; McDonald et al, 2002) , and contribute to general health deterioration, likely to impact independently on breast cancer prognosis (Sjol et al, 2003) . Obesity, for example, is a risk factor for post-menopausal breast cancer (approximately 75% of cases) (Sonnenschein et al, 1999) and can exacerbate breast cancer prognosis (Bastarrachea et al, 1994; Abrahamson et al, 2006; Carmichael, 2006) . Comparable to trends in other western countries (Boniface, 2006) , obesity prevalence increased in Denmark by 7.1% from 1987 to 2001, particularly after 1998 (Sjol et al, 2003; Bendixen et al, 2004) and overweight prevalence in women increased by 10% (Bendixen et al, 2004) . Furthermore, alcohol consumption (wine and hard liquor) and smoking have increased in Denmark over the past 10 -20 years (Statistics Denmark, 2006) . Consumption of alcohol before breast cancer diagnosis is thought to intimate a poorer prognosis (Thun et al, 1997; McDonald et al, 2002) , but findings are inconsistent (Ewertz, 1993) . The timing of the increased prevalence of obesity, alcohol consumption, and smoking corresponds with, and may, therefore, have impacted on survival among patients with severe comorbidities. The main strengths of our study are its large size, the uniformly organised health-care system facilitating a population-based design with accurate survival estimates, reduced selection bias, and complete follow-up. Our study has some limitations: it may be prone to incidence-prevalence bias. Prevalent comorbid disease includes cases with long-term survival, who therefore have better survival than incident cases, in whom the full severity of comorbidity is represented (Goldman et al, 1983) . To minimise such bias, we included comorbidity history recorded up to 10 years before breast cancer diagnosis. We used the Charlson comorbidity index to measure comorbidity, which has been used to assess the impact of comorbidities in many disease settings (Greenfield et al, 1993; Newschaffer et al, 1997; Horton et al, 2001; Mandelblatt et al, 2001) . The Charlson index has some limitations, however: (a) it does not incorporate a measure of function (Greenfield et al, 1987) ; patients with identical scores can vary in comorbid disease severity, for example, manageable diabetes is classified within the same category as severely debilitating chronic obstructive pulmonary disease (Charlson score '1'). (b) The Charlson index is based on discharge diagnoses, which may not be entirely accurate. (c) The registration of comorbidities may have changed over the years, likely towards more complete registration.
In conclusion, we found a negative impact of comorbidity on breast cancer mortality. As breast cancer is the most commonly diagnosed cancer among women and the fifth most common cause of cancer-related death in women (Parkin et al, 2005) , our observed increase in mortality among patients with severe comorbidity is of clinical and public health concern.
